Drugs / PF804
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01608022 | Jul 2012 → Apr 2015 | esophageal squamous cell carcinoma | Yonsei University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01608022 ↗ |
| Action | Inhibit | “PF-00299804 is a second-generation quinazoline-based irreversible pan-HER inhibitor.” NCT01608022 ↗ |
| Modality | Small molecule | “PF-00299804 is a second-generation quinazoline-based irreversible pan-HER inhibitor.” NCT01608022 ↗ |
| Route | Oral | “45 mg p.o. daily and continuously” NCT01608022 ↗ |